Last reviewed · How we verify
NCT07072221
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
NA trial testing BCL regimen in Peripheral T-cell Lymphoma in 40 participants. Currently enrolling.
1 August 2029
Quick facts
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 November 2024 |
| Primary completion | 1 August 2029 |
| Estimated completion | 1 November 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- BCL regimen — full drug profile →
- Cohort 1 (ASCT-eligible)
- Cohort 2 (ASCT--ineligible) — full drug profile →
Conditions studied
- Peripheral T-cell Lymphoma — all drugs for Peripheral T-cell Lymphoma →
Sponsor
The First Affiliated Hospital of Soochow University
Who can join
18 and older, any sex, with Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy and safety of bendamustine combined with chidamide and lenalidomide in R/R PTCL patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.
Casan JML, Ong XJ, van der Weyden C, Yannakou CK, et al · · 2025 · cited 1× · PMID 41295262 · DOI 10.3390/jpm15110560
Verify or expand the search:
- PubMed search for NCT07072221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral T-cell Lymphoma
Currently open trials in the same condition.
- NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT06914037 — A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies · Phase 1 · recruiting
- NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL · Phase 1, PHASE2 · recruiting
- NCT06421948 — Linperlisib Combined With Chidamide in Patients With PTCL · Phase 1, PHASE2 · recruiting
Other The First Affiliated Hospital of Soochow University trials
Trials by the same sponsor.
- NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
- NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
- NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07072221 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07072221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing